Antiparasite segment is expected to contribute largest share in global infectious disease treatment market by 2016 end owing to the evolution of different disease indication through parasites
New York, NY -- (SBWIRE) -- 01/27/2017 -- Infectious diseases are the type of disorders caused by different organisms such as bacteria, virus, fungi or parasites. The organism can be harmful or helpful to the human body and under some conditions the organism causes different diseases. Diseases can be transferable from person to person, bites of insects and animals, through ingestion of contaminated food or water or being exposed to organisms in the environment. Signs and symptoms such as fever, fatigue, etc. vary depending on the type of organism causing the infection. Mild infection can be treated through prescribed medicines by physicians while life threatening infections may require hospitalization. Many infectious disease such as measles and chickenpox have been controlled through vaccination programs. Taking precautions such as creating clean environment, proper sanitization and thorough hand-washing also helps to protect individuals from most infectious diseases.
A sample of this report is available upon request @ http://www.persistencemarketresearch.com/samples/12733
Cholera infection re-entered Peru in 1996 and spread through the existing sanitation and water systems, causing over 3,000 deaths. Seafood exports were embargoed from Peru and tourism decreased, costing an estimated loss of at least US$ 770 Mn to the Peruvian economy in one year. International military networks such as the U.S. Department of Defense Global Emerging Infections System (DoD-GEIS), private clinics, individual scientists and public health practitioners are the networks which provide the formal information sources for the spread of infectious diseases. Easy approval from Food and Drug Administration (FDA) for drug regulation in market, and role of major key players also plays an important role for the infectious disease treatment market.
The global market for infectious disease treatment market is segmented on basis of disease type, treatment type, diagnosis type, end user and geography:
Segmentation by Disease Type
Segmentation by Treatment Type
Segmentation by Diagnosis Type
Segmentation by End User
The bacterial disease type segment is expected to witness remarkable growth in the global infectious disease market due to the increasing evolution of different microorganisms in different environmental conditions, unhealthy food habits among population, and increase in prevention care facilities for patients which will address to various research, other prevention methods, and education in order to prevent the epidemiology of infectious diseases. The parasitic disease and viral disease segment type is expected to register significant growth through 2024 due to the emergence of different mutation technologies and chemical utilization and upcoming research laboratories in emerging countries.
Based on treatment type, antiparasite segment is expected to contribute largest share in global infectious disease treatment market by 2016 end owing to the evolution of different disease indication through parasites. For instance, Zika Virus is transmitted through mosquitoes. Based on diagnosis test type, the global infectious disease treatment market has been segmented into laboratory test, biopsies and imaging scans. Laboratory test segment is expected to contribute the maximum share among diagnosis test type segments. Based on the end user, hospital segment is projected to have the largest market share among other segments due to the availability of trained professionals, easy availability of diagnosis methods, and reimbursement policies for major treatment procedures.
On the basis of regional presence, global infectious disease treatment market is segmented into five key regions viz. North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America is expected to lead the global infectious disease treatment market due to unhealthy food intake habits of the population, improper sanitization, new disease evolution and environmental conditions. According to the WHO statistics for the year 2011, prevalence of infectious disease treatment is high in developed countries such as U.S. and U.K. More precautions are being undertaken in the MEA region due to the prevalence of various viral diseases which have a potential to spread and create an epidemic situation for the world population.
To view TOC of this report is available upon request @ http://www.persistencemarketresearch.com/toc/12733
Some of the major players in global infectious disease treatment market are Janssen Global Services, Merck & Co., GlaxoSmithKline Pharmaceutical, Inc., Pfizer, F. Hoffmann-La Roche, Novartis, Achillion Pharmaceuticals, Auritec Pharmaceuticals, Isis Pharmaceuticals and Gilead Sciences. etc.